Q-omics provides the consensus-scored ANKUB1 profile across patient tissues and cancer cell-line models. ANKUB1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ANKUB1 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, ANKUB1 RNA expression shows 13,730 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, LUAD, and UVM as cancer lineages where ANKUB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKUB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKUB1 survival associations across molecular data types. ANKUB1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKUB1 RNA expression–survival associations across cancer types. High ANKUB1 expression shows unfavorable associations in ACC, KIRC, LGG, DLBC and LUAD, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ANKUB1 RNA expression.
This table summarizes ANKUB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANKUB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKUB1 shows lower tumor expression in LUAD, LUSC and BRCA and higher tumor expression in COAD, HNSC and CHOL. The LUAD box plot shows higher ANKUB1 RNA expression in normal versus tumor tissue (log2 FC = −0.511, t-test p < 0.001).
This table shows molecular features associated with ANKUB1 in patient tissues and cancer cell lines. In patient samples, ANKUB1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKUB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
